Receive $200 for creating an Interactive Brokers account using our link: Create IBKR account. Read our Interactive Brokers analysis

Ticker
FAGR.BR

Price
22.70
Stock movement up
+0.30 (1.34%)
Company name
Fagron NV
Exchange
(BR
,
Currency
EUR
)
Sector
Healthcare >
Drug Manufacturers - Specialty & Generic
Market cap
1.66B
Ent value
2.16B
Price/Sales
0.91
Price/Book
2.99
Div yield
-
Div growth
-
Growth years
-
FCF payout
26.14%
Trailing P/E
9.69
Forward P/E
13.99
PEG
-
EPS growth
8.53%
1 year return (CAGR)
14.76%
3 year return (CAGR)
16.38%
5 year return (CAGR)
2.58%
10 year return (CAGR)
16.25%
Last updated: 2026-03-13

DIVIDENDS

FAGR.BR does not pay dividends or no data was received

VALUATION

Valuation Ratios

Loading...
Valuation Ratios data
Trailing P/E9.69
Price to OCF7.85
Price to FCF9.24
Price to EBITDA4.64
EV to EBITDA6.04

Valuation (Sales/Book Value)

Loading...
Valuation (Sales/Book Value) data
Price to Sales0.91
Price to Book2.99
EV to Sales1.19

FINANCIALS

Per share

Loading...
Per share data
Current share count73.24M
EPS (TTM)2.34
FCF per share (TTM)2.46

Income statement

Loading...
Income statement data
Revenue (TTM)1.82B
Gross profit (TTM)783.66M
Operating income (TTM)278.32M
Net income (TTM)171.57M
EPS (TTM)2.34
EPS (1y forward)1.62

Margins

Loading...
Margins data
Gross margin (TTM)42.96%
Operating margin (TTM)15.26%
Profit margin (TTM)9.41%

Balance Sheet

Loading...
Please create a free account or log in to access this chart
Balance Sheet data
Cash184.90M
Net receivables95.24M
Total current assets462.84M
Goodwill471.10M
Intangible assets99.67M
Property, plant and equipment0.00
Total assets1.24B
Accounts payable137.59M
Short/Current long term debt512.78M
Total current liabilities218.98M
Total liabilities686.87M
Shareholder's equity556.26M
Net tangible assets0.00

Cash flow

Loading...
Please create a free account or log in to access this chart
Cash flow data
Operating cash flow (TTM)211.79M
Capital expenditures (TTM)41.48M
Free cash flow (TTM)179.96M
Dividends paid (TTM)47.05M

Financial returns

Loading...
Please create a free account or log in to access this chart
Financial returns data
Return on Equity30.84%
Return on Assets13.80%
Return on Invested Capital30.21%
Cash Return on Invested Capital31.69%

STOCK INFORMATION

Stock chart

Loading...
Stock price data
Open22.40
Daily high22.85
Daily low22.20
Daily Volume106K
All-time high41.63
1y analyst estimate26.75
Beta0.31
EPS (TTM)2.34
Dividend per share0.00
Ex-div date19 May 2025
Next earnings date9 Apr 2026

Downside potential

Loading...
Downside potential data
FAGR.BRS&P500
Current price drop from All-time high-45.47%-1.82%
Highest price drop-90.66%-56.47%
Date of highest drop14 Dec 20159 Mar 2009
Avg drop from high-41.11%-10.84%
Avg time to new high41 days12 days
Max time to new high2947 days1805 days
COMPANY DETAILS
FAGR.BR (Fagron NV) company logo
Marketcap
1.66B
Marketcap category
Small-cap
Description
Fagron NV, a pharmaceutical compounding company, delivers personalized pharmaceutical care to hospitals, pharmacies, clinics, patients, and worldwide. It operates through three segments: Essentials, Brands, and Compounding Services. The company's products include DiluCap, a line of excipients to compound every capsule formulation; Imuno TF Complex helps in regulation of immune responses; Pigmerise, a natural phytocomplex for hypopigmentation disorders, such as vitiligo; Pentravan uses for avoiding first-pass metabolism and preventing gastrointestinal erosion; Nourisil MD, a first line therapy for prevention and treatment of scars ang keloids; Neogen, a line of hair care products; TrichoConcept used to treat alopecia; Fagron Advanced Derma for basic skincare, compound pharmaceutical treatment, and individualized dermatological care; SyrSpend SF that provides pharmaceutical stability, dosage consistency, and patient comfort; and Cleoderm, a topical cream used for the compounding of personalized dermatological treatments. It also offers education and professional development of prescribers and pharmacists through the Fagron Academy. The company was formerly known as Arseus NV and changed its name to Fagron NV in January 2015. Fagron NV was founded in 1990 and is based in Nazareth, Belgium.
Employees
3989
Investor relations
-
CEO
Country
Belgium
City
Stock type
-
CCC status
-
Dividend Frequency
-
EVENTS AND PRESENTATIONS
EventsPresentations
Loading...
UNDERSTAND THE BUSINESS
Loading...
COMPANY NEWS
All newsPress releases
Regulated information Nazareth (Belgium)/Rotterdam (The Netherlands), 13 March 2026 – 6 PM CET Disclosure of a transparency notification from Mawer Investment Management Ltd Pursuant to the Belgian ac...
March 13, 2026
Fagron (ENXTBR:FAGR) has completed the acquisition of Vepakum, expanding its presence in Latin America. The deal adds new verticals and product lines to Fagron’s existing pharmaceutical compounding ac...
March 8, 2026
Regulated informationNazareth (Belgium)/Rotterdam (The Netherlands), 6 March 2026 7AM CET Fagron publishes its Annual Report 2025 Fagron, the leading global player in pharmaceutical compounding, today...
March 6, 2026
Regulated information – inside informationNazareth (Belgium)/Rotterdam (The Netherlands), 3 March 2026 – 7:00AM Fagron completes acquisition of Vepakum Fagron, the leading global player in pharmaceuti...
March 3, 2026
Regulated information Nazareth (Belgium)/Rotterdam (The Netherlands), 27 02 2026 – 6PM CET Disclosure of a transparency notification from AOC Pharma S.à r.l. Pursuant to the Belgian Act of 2 May 2007 ...
February 27, 2026
Regulated information – inside information Nazareth (Belgium)/Rotterdam (The Netherlands), 26 February 2026 – 6:30PM Fagron completes strategic acquisition of Pharmavit Europe, strengthening its leade...
February 26, 2026
Fagron (ENXTBR:FAGR) has drawn investor interest after recent share price moves, supported by reported revenue of €918.75m and net income of €85.687m. This has prompted a closer look at its valuation ...
February 13, 2026
Regulated informationNazareth (Belgium)/Rotterdam (The Netherlands), 12 February 2026 – 7AM CET Fagron continues its outstanding performance in FY 2025 with 9.2% topline growth and 10.9% increase in R...
February 12, 2026
Regulated information - inside informationNazareth (Belgium)/Rotterdam (The Netherlands), 5 February 2026 Fagron obtains regulatory clearance for the acquisition of Vepakum in Brazil and completes the...
February 5, 2026
Regulated information - inside informationNazareth (Belgium)/Rotterdam (The Netherlands), 12 January 2026 – 7:00 AM CET Fagron announces the completion of the acquisition of University Compounding Pha...
January 12, 2026
Next page